Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025
Bio-Techne (NASDAQ: TECH) will showcase its latest innovations at the American Society of Gene & Cell Therapy (ASGCT) 2025 meeting in New Orleans from May 13-17. Key highlights include the new RNAscope™ protease-free workflow for AAV vector visualization, ProPak™ GMP cytokines in dose-optimized bags, and the next-generation Simple Western Leo™ System capable of processing 100 samples in 3 hours.
The company will host a symposium on May 14th featuring presentations from industry leaders, including speakers from Dyno Therapeutics and Tessera Therapeutics. An additional talk on protein quantitation applications will be held on May 15th with speakers from Sangamo Therapeutics and Nervosave Therapeutics.
Bio-Techne (NASDAQ: TECH) presenterà le sue ultime innovazioni al congresso American Society of Gene & Cell Therapy (ASGCT) 2025 a New Orleans dal 13 al 17 maggio. Tra i punti salienti ci sono il nuovo workflow RNAscope™ senza proteasi per la visualizzazione dei vettori AAV, le citochine ProPak™ GMP in sacche con dosaggio ottimizzato e il sistema di nuova generazione Simple Western Leo™ in grado di analizzare 100 campioni in 3 ore.
La società organizzerà un simposio il 14 maggio con presentazioni di esperti del settore, tra cui relatori di Dyno Therapeutics e Tessera Therapeutics. Il 15 maggio si terrà un ulteriore intervento sulle applicazioni della quantificazione proteica con ospiti di Sangamo Therapeutics e Nervosave Therapeutics.
Bio-Techne (NASDAQ: TECH) presentará sus últimas innovaciones en la reunión de la American Society of Gene & Cell Therapy (ASGCT) 2025 en Nueva Orleans del 13 al 17 de mayo. Entre los aspectos destacados se incluyen el nuevo flujo de trabajo RNAscope™ sin proteasas para la visualización de vectores AAV, las citoquinas ProPak™ GMP en bolsas con dosis optimizadas y el sistema de próxima generación Simple Western Leo™ capaz de procesar 100 muestras en 3 horas.
La compañía organizará un simposio el 14 de mayo con presentaciones de líderes de la industria, incluidos ponentes de Dyno Therapeutics y Tessera Therapeutics. El 15 de mayo se realizará una charla adicional sobre aplicaciones de cuantificación de proteínas con ponentes de Sangamo Therapeutics y Nervosave Therapeutics.
Bio-Techne (NASDAQ: TECH)는 5월 13일부터 17일까지 뉴올리언스에서 열리는 미국 유전자 및 세포 치료학회(ASGCT) 2025 회의에서 최신 혁신 기술을 선보일 예정입니다. 주요 하이라이트로는 AAV 벡터 시각화를 위한 RNAscope™ 프로테아제 프리 워크플로우, 용량 최적화된 백에 담긴 ProPak™ GMP 사이토카인, 그리고 3시간 내에 100개 샘플을 처리할 수 있는 차세대 Simple Western Leo™ 시스템이 있습니다.
회사는 5월 14일에 Dyno Therapeutics와 Tessera Therapeutics의 연사를 포함한 업계 리더들의 발표가 있는 심포지엄을 개최합니다. 또한 5월 15일에는 Sangamo Therapeutics와 Nervosave Therapeutics의 연사들이 참여하는 단백질 정량화 응용에 관한 추가 강연이 진행됩니다.
Bio-Techne (NASDAQ : TECH) présentera ses dernières innovations lors de la réunion de la American Society of Gene & Cell Therapy (ASGCT) 2025 à la Nouvelle-Orléans du 13 au 17 mai. Parmi les points forts figurent le nouveau workflow RNAscope™ sans protéase pour la visualisation des vecteurs AAV, les cytokines ProPak™ GMP en poches à dose optimisée, ainsi que le système de nouvelle génération Simple Western Leo™ capable de traiter 100 échantillons en 3 heures.
L'entreprise organisera un symposium le 14 mai avec des présentations de leaders du secteur, incluant des intervenants de Dyno Therapeutics et Tessera Therapeutics. Une conférence supplémentaire sur les applications de quantification des protéines aura lieu le 15 mai, avec des intervenants de Sangamo Therapeutics et Nervosave Therapeutics.
Bio-Techne (NASDAQ: TECH) wird seine neuesten Innovationen auf der American Society of Gene & Cell Therapy (ASGCT) 2025 Tagung in New Orleans vom 13. bis 17. Mai vorstellen. Zu den Highlights zählen der neue RNAscope™ proteasefreie Workflow zur Visualisierung von AAV-Vektoren, ProPak™ GMP Zytokine in dosisoptimierten Beuteln und das nächste Generation Simple Western Leo™ System, das 100 Proben in 3 Stunden verarbeiten kann.
Das Unternehmen wird am 14. Mai ein Symposium veranstalten, das Präsentationen von Branchenführern beinhaltet, darunter Redner von Dyno Therapeutics und Tessera Therapeutics. Am 15. Mai findet ein weiterer Vortrag zu Proteinquantifizierungsanwendungen mit Referenten von Sangamo Therapeutics und Nervosave Therapeutics statt.
- None.
- None.
Bio-Techne will feature its cutting-edge advancements for cell and gene therapy development and manufacturing at booth 1537. Highlights include the new RNAscope™ protease-free workflow for visualization of biodistribution of AAV vectors, transgene mRNA, small RNAs (ASO, siRNA, miRNA) along with functional RNA and protein markers. Bio-Techne's booth will also showcase its solutions to improve cell therapy workflows, including the ProPak™ GMP cytokines in dose-optimized, single-use bags with weldable tubing for closed-system cell therapy manufacturing, and new AI-modified, designer proteins. The next-generation Simple Western Leo™ System will also be featured, with this state-of-the-art instrument enabling the simultaneous processing of up to 100 samples in a single 3-hour run.
Leading researchers along with Maithreyan Srinivasan, PhD, Chief Scientific Officer, Advanced Cell Diagnostics (ACD), a Bio-Techne brand, will present the latest innovations with RNAscope technology at ACD's symposium on Wednesday, May 14th at 8:30 am in room 383-385. This session will highlight NextGen RNAscope™ Multiomics Solutions for Spatial Precision: AAV, small RNA, CAR-T, and Beyond. Our distinguished guest speakers include:
- Adrian Veres, MD, PhD, Cofounder & Chief Scientific Officer at Dyno Therapeutics will present on "In Vivo Validation of AI-designed AAV Capsids for Targeted Gene Delivery to NHPs."
- William (Wes) Salomon, PhD, Senior Director, Delivery Biology, Tessera Therapeutics will speak on "Visualizing RNA Gene Writer Activity in Mouse Liver for the Potential Therapeutic Correction of Monogenic Disease Mutations."
Another talk, moderated by Edward Pavina (Bio-Techne) will be presented on Thursday, May 15th from 12:15 – 1:15 PM in Room 383: "Protein Quantitation Applications to Advance Gene Therapy Development – From Discovery Through Analytical Development" with guest Speakers Julyana Acevedo PhD, Analytical Development Scientist, Sangamo Therapeutics and Nicolas Tricaud PhD, Co-founder, CEO/CS, Nervosave Therapeutics.
"Bio-Techne is leading the forefront of advancing cell and gene therapy development with cutting edge tools and technologies," commented Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "This conference highlights the frontier of pre-clinical and clinical advanced therapeutic development and paves the way for building safe and effective therapies for a multitude of disorders."
For Research Use Only. Not for use in diagnostic procedures.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-showcase-next-generation-solutions-for-gene-and-cell-therapy-at-american-society-of-gene--cell-therapy-2025-302449766.html
SOURCE Bio-Techne Corporation
FAQ
What new products will Bio-Techne (TECH) showcase at ASGCT 2025?
When and where is Bio-Techne presenting at ASGCT 2025?
Who are the key speakers at Bio-Techne's ASGCT 2025 symposium?
What is the Simple Western Leo System's processing capability?
